

info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101

**Tradename:** Revital-Eyes

**Code:** 16671

CAS #: 7732-18-5 & 68333-16-4 & 84650-60-2 & 84961-57-9 & 1686112-36-6 (or)

68333-16-4 & 58-08-2

Test Request Form #: 42

Lot #: SN130813-2

**Sponsor:** Active Concepts, LLC; 107 Technology Drive Lincolnton, NC 28092

Study Director: Erica Segura

Principle Investigator: Meghan Darley

### **Test Performed:**

High Resolution Ultrasound Skin-Imaging Assay

#### Introduction

An *in-vivo* study was conducted over a period of four weeks to evaluate the effect on skin density of **Revital-Eyes**. 10 M/F subjects between the ages of 23-45 participated in the study. Results indicate that this material is capable of significantly improving skin density compared to the control.

#### **Materials**

A. Equipment: DermaLab Skin Combo (Ultrasound Probe)

### **Methods**

Ultrasound skin imaging is based on measuring the acoustic response after an acoustic pulse is sent into the skin. The energy of the acoustic pulse is low and will not affect the skin in any way. When the acoustic pulse is emitted and hits different areas of the skin, part of the pulse will be reflected and part will be transmitted further into the skin. The reflected signal travels back and is picked up by the ultrasound transducer. After processing the signal, a cross-sectional image appears on the screen. This image represents an intensity, or amplitude, analysis of the signals.

The intensity of the signals that are received refer to a color scale. Dark colors represent areas of the skin with low reflection. This means that there are no changes or very small changes in density between the structures in the skin. Bright colors represent areas with strong reflections, signifying substantial changes in density between structures.

Information contained in this technical literature is believed to be accurate and is offered in good faith for the benefit of the customer. The company, however, cannot assume any liability or risk involved in the use of its chemical products since the conditions of use are beyond our control. Statements concerning the possible use of our products are not intended as recommendations to use our products in the infringement of any patent. We make no warranty of any kind. expressed or implied. other than that the material conforms to the applicable standard specification.

Page 1 of 4 Version#4/05-25-21/Form#75



info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101

10 volunteers M/F between the ages of 23 and 45 and who were known to be free of any skin pathologies participated in this study. The DermaLab ultrasound probe was used to determine the skin density of the subject's volar forearms. Baseline elasticity readings were taken on day one of the study.

Following initial measurements, all subjects were asked to apply 2 mg of each test material on their volar forearms. Measurements were taken immediately after application of test materials and then weekly for 4 weeks. The test material consisted of 2% **Revtial-Eyes** in a base lotion.

For added perspective, measurements of an untreated test site and a site treated with a base lotion (Cetaphil Moisturizing for All Skin Types) were recorded.

#### Results

**Revital-Eyes** showed improvements in skin density at a 2.0% concentration. Please note, each value is an average of three consecutive readings per test site.

| Ultrasound          |              | T = 0 | T = 1 Week | T = 2 Weeks | T = 3 Weeks | T = 4 Weeks |
|---------------------|--------------|-------|------------|-------------|-------------|-------------|
| Panelist 1          | Experimental | 52    | 53         | 65          | 72          | 81          |
|                     | Base Lotion  | 57    | 58         | 62          | 67          | 78          |
|                     | Untreated    | 75    | 65         | 64          | 71          | 69          |
| Panelist 2          | Experimental | 66    | 87         | 86          | 84          | 89          |
|                     | Base Lotion  | 83    | 83         | 82          | 81          | 85          |
|                     | Untreated    | 70    | 75         | 62          | 65          | 74          |
| Panelist 3          | Experimental | 48    | 54         | 54          | 65          | 69          |
|                     | Base Lotion  | 27    | 41         | 51          | 60          | 53          |
|                     | Untreated    | 71    | 72         | 59          | 64          | 65          |
|                     | Experimental | 73    | 75         | 81          | 94          | 89          |
| Panelist 4          | Base Lotion  | 68    | 72         | 74          | 79          | 75          |
|                     | Untreated    | 52    | 61         | 70          | 68          | 66          |
|                     | Experimental | 67    | 82         | 62          | 65          | 82          |
| Panelist 5          | Base Lotion  | 62    | 65         | 60          | 65          | 78          |
|                     | Untreated    | 62    | 66         | 54          | 69          | 65          |
|                     | Experimental | 52    | 52         | 51          | 64          | 58          |
| Panelist 6          | Base Lotion  | 57    | 61         | 51          | 61          | 69          |
|                     | Untreated    | 63    | 77         | 81          | 75          | 69          |
| Panelist 7          | Experimental | 70    | 83         | 93          | 80          | 90          |
|                     | Base Lotion  | 92    | 86         | 80          | 79          | 72          |
|                     | Untreated    | 50    | 54         | 45          | 63          | 52          |
|                     | Experimental | 45    | 31         | 33          | 48          | 36          |
| Panelist 8          | Base Lotion  | 44    | 52         | 40          | 49          | 55          |
|                     | Untreated    | 52    | 53         | 57          | 69          | 57          |
| Panelist 9          | Experimental | 85    | 66         | 55          | 50          | 62          |
|                     | Base Lotion  | 81    | 75         | 81          | 75          | 73          |
|                     | Untreated    | 70    | 72         | 71          | 75          | 69          |
| Panelist 10         | Experimental | 65    | 70         | 72          | 77          | 79          |
|                     | Base Lotion  | 57    | 69         | 61          | 72          | 75          |
|                     | Untreated    | 51    | 39         | 49          | 65          | 55          |
| Number of Panelists |              | 10    | 10         | 10          | 10          | 10          |

Figure 1: Individual Raw Data

Information contained in this technical literature is believed to be accurate and is offered in good faith for the benefit of the customer. The company, however, cannot assume any liability or risk involved in the use of its chemical products since the conditions of use are beyond our control. Statements concerning the possible use of our products are not intended as recommendations to use our products in the infringement of any patent. We make no warranty of any kind. expressed or implied. other than that the material conforms to the applicable standard specification.

Page 2 of 4 Version#4/05-25-21/Form#75



info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101

| Averages  | T = 0 | T = 1 Week | T = 2 Weeks | T = 3 Weeks | T = 4 Weeks |
|---|-------|------------|-------------|-------------|-------------|
| Experimental (2.0% Revital-<br>Eyes in Base Lotion) | 62.3  | 65.3       | 65.2        | 69.9        | 73.5        |
| Base Lotion   | 62.8  | 66.2       | 64.2        | 68.8        | 71.3        |
| Untreated   | 61.6  | 63.4       | 61.2        | 68.4        | 64.1        |

Figure 2: Average values

| Percent (%) Change  | T = 0  | T = 1 Week | T = 2 Weeks | T = 3 Weeks | T = 4 Weeks |
|---|--------|------------|-------------|-------------|-------------|
| Base Lotion vs. Untreated   | 1.95%  | 4.42%      | 4.90%       | 0.58%       | 11.23%      |
| Experimental (2.0% Revital-Eyes<br>+ Base Lotion) vs. Untreated           | 1.14%  | 3.00%      | 6.54%       | 2.19%       | 14.66%      |
| Experimental (2.0% AC Revital-<br>Eyes in Base Lotion) vs. Base<br>Lotion | -0.80% | -1.36%     | 1.56%       | 1.60%       | 3.09%       |

Figure 3: Percent change

### **Collagen Ultrasound**

### **Comparative Analysis of Skin Density**




Figure 4: Percent difference in skin density recordings between test materials.

Information contained in this technical literature is believed to be accurate and is offered in good faith for the benefit of the customer. The company, however, cannot assume any liability or risk involved in the use of its chemical products since the conditions of use are beyond our control. Statements concerning the possible use of our products are not intended as recommendations to use our products in the infringement of any patent. We make no warranty of any kind. expressed or implied. other than that the material conforms to the applicable standard specification.



info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101

### **Discussion**

As evidenced in a 4 week efficacy study of **Revital-Eyes** on skin, skin density was improved by 3.00% after one week and by 14.66% after 4 weeks when compared to the untreated control. When compared to the base cream **Revital-Eyes** improved skin density by 3.09% better than the base lotion after four weeks. Results indicate that **Revital-Eyes** is capable of improving skin density when compared to both the untreated control as well as the base lotion. **Revital-Eyes** has a strong positive effect on skin's density when used at recommended use levels.

Information contained in this technical literature is believed to be accurate and is offered in good faith for the benefit of the customer. The company, however, cannot assume any liability or risk involved in the use of its chemical products since the conditions of use are beyond our control. Statements concerning the possible use of our products are not intended as recommendations to use our products in the infringement of any patent. We make no warranty of any kind. expressed or implied. other than that the material conforms to the applicable standard specification.